Cytokinetics, Incorporated Business Finance Contracts & Agreements
57 Contracts & Agreements
- Funding Agreements (1 contract)
- Indenture Agreements (3)
- Loan Agreements (10)
- Purchase Agreements (7)
- Registration Rights Agreements (2)
- Stock Agreements (16)
- Subscription Agreements (1)
- Trust Agreements (1)
- Underwriting Agreements (8)
- Warrant Agreements (8)
- Common Stock Option and Purchase Agreement, dated May 22, 2024, by and between Royalty Pharma Investments 2019 ICAV and the Company (Filed With SEC on August 9, 2024)
- CK-586 Revenue Participation Right Purchase Agreement, dated May 22, 2024, by and between Royalty Pharma Investments 2019 ICAV and the Company (Filed With SEC on August 9, 2024)
- 2024 Development Funding Loan Agreement, dated May 22, 2024, by and among Royalty Pharma Development Funding, LLC and the Company (Filed With SEC on August 9, 2024)
- Amendment No. 1, dated May 22, 2024, to Revenue Participation Right Purchase Agreement, dated January 7, 2022, by and between Royalty Pharma Investments 2019 ICAV and the Company (Filed With SEC on August 9, 2024)
- Third Amendment, dated May 22, 2024, to Development Funding Loan Agreement, dated January 7, 2022, by and among Royalty Pharma Development Funding, LLC and the Company (Filed With SEC on August 9, 2024)
- Underwriting Agreement, dated as of May 22, 2024, by and among Cytokinetics, Incorporated, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC (Filed With SEC on May 28, 2024)
- Cytokinetics, Incorporated Amended and Restated 2015 Employee Stock Purchase Plan (Filed With SEC on May 17, 2024)
- Indenture, dated as of July 6, 2022, between Cytokinetics, Incorporated and U.S. Bank Trust Company, National Association, as trustee (Filed With SEC on July 6, 2022)
- Revenue Participation Right Purchase Agreement, dated January 7, 2022, by and between the Company and Royalty Pharma Investments 2019 ICAV (Filed With SEC on February 25, 2022)
- Amendment No. 1 to Royalty Purchase Agreement, dated January 7, 2022, by and between the Company and RPI Finance Trust (Filed With SEC on February 25, 2022)
- Development Funding Loan Agreement, dated January 7, 2022, by and among Royalty Pharma Development Funding, LLC and the Company (Filed With SEC on February 25, 2022)
- Common Stock Purchase Agreement, dated December 20, 2021, by and between the Company and RTW Venture Fund Limited (Filed With SEC on February 25, 2022)
- Common Stock Purchase Agreement, dated December 20, 2021, by and between the Company and RTW Innovation Master Fund, Ltd (Filed With SEC on February 25, 2022)
- Common Stock Purchase Agreement, dated December 20, 2021, by and between the Company and RTW Master Fund, Ltd (Filed With SEC on February 25, 2022)
- Fourth Amendment to Loan and Security Agreement, dated June 30, 2021, by and among the Company, Oxford Finance LLC and Silicon Valley Bank (Filed With SEC on November 5, 2021)
- Underwriting Agreement, dated as of July 20, 2021, by and among Cytokinetics, Incorporated, J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC (Filed With SEC on July 21, 2021)
- Third Amendment to Loan and Security Agreement, dated July 16, 2020, by and among the Company, Oxford Finance LLC and Silicon Valley Bank (Filed With SEC on November 6, 2020)
- Form of Common Stock Purchase Agreement, dated July 14, 2020 (Filed With SEC on November 6, 2020)
- Royalty Purchase Agreement, dated July 14, 2020, by and between the Company and Dolya Holdco 19 Designated Activity Company (Filed With SEC on November 6, 2020)
- Funding Agreement, dated July 14, 2020, by and between the Company and Dolya Holdco 19 Designated Activity Company (Filed With SEC on November 6, 2020)
- Underwriting Agreement, dated as of July 16, 2020, by and among Cytokinetics, Incorporated, Goldman Sachs & Co. LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co (Filed With SEC on July 17, 2020)
- Second Amendment to Loan and Security Agreement, dated as of November 7, 2019, by and among the Company, Oxford Finance LLC and Silicon Valley Bank (Filed With SEC on November 13, 2019)
- First Amendment to Loan and Security Agreement, dated as of November 6, 2019, by and among the Company, Oxford Finance LLC and Silicon Valley Bank (Filed With SEC on November 13, 2019)
- First Supplemental Indenture, dated November 13, 2019, between the Company and U.S. Bank National Association, as Trustee (including the form of 4.00% Convertible Senior Note due... (Filed With SEC on November 13, 2019)
- Base Indenture, dated November 13, 2019, between the Company and U.S. Bank National Association, as Trustee (Filed With SEC on November 13, 2019)
- Underwriting Agreement, dated November 7, 2019, by and between the Company and Morgan Stanley & Co. LLC as representative of the several underwriters named therein (Filed With SEC on November 13, 2019)
- Loan and Security Agreement, dated as of May 17, 2019, by and among the Company, Oxford Finance LLC and Silicon Valley Bank (Filed With SEC on August 9, 2019)
- Form of Warrant Issuable to Silicon Valley Bank (Filed With SEC on August 9, 2019)
- Form of Warrant Issuable to Oxford Finance LLC (Filed With SEC on August 9, 2019)
- Second Amendment to Loan and Security Agreement by and among the Company, Oxford Finance LLC and Silicon Valley Bank, dated as of October 27, 2017 (Filed With SEC on March 5, 2018)
- 5,260,000Shares of Common Stock CYTOKINETICS, INCORPORATED UNDERWRITING AGREEMENT (Filed With SEC on May 9, 2017)
- CYTOKINETICS, INCORPORATED COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on March 6, 2017)
- ROYALTYPURCHASE AGREEMENT BY AND BETWEEN CYTOKINETICS, INCORPORATED AND RPIFINANCE TRUST DATED AS OF FEBRUARY 1, 2017 TABLE OF CONTENTS (Filed With SEC on March 6, 2017)
- LOAN ANDSECURITY AGREEMENT (Filed With SEC on March 3, 2016)
- WARRANT TO PURCHASESTOCK (Filed With SEC on March 3, 2016)
- CYTOKINETICS, INCORPORATED Shares of Common Stock (par value$0.001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on September 4, 2015)
- CYTOKINETICS, INCORPORATED 2015 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS:FEBRUARY 3, 2015 APPROVED BY THE STOCKHOLDERS:MAY 20, 2015 EFFECTIVE DATE: NOVEMBER... (Filed With SEC on August 5, 2015)
- CYTOKINETICS, INCORPORATED COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on December 23, 2014)
- 4,375,000 Shares of Common Stock CYTOKINETICS, INCORPORATED UNDERWRITING AGREEMENT (Filed With SEC on February 20, 2014)
- CYTOKINETICS, INCORPORATED 2004 EMPLOYEE STOCK PURCHASE PLAN (As amended by the Board of Directors on February 6, 2013; stockholder approval May 22, 2013; updated following... (Filed With SEC on August 7, 2013)
